EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma

Danielle S Wallace iD, Yashashree Gupta, Carla Casulo, Wendy Osborne iD

HemaSphere · 2026-11 · 10 (11)

DOI: 10.1002/hem3.70489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift HemaSphere, online erschienen am 03.11.2026. Verfasst von Danielle S Wallace und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wilmot Cancer Institute University of Rochester Medical Center Rochester New York United States of America. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large B‐cell lymphoma (LBCL) is cured in most patients with first‐line chemoimmunotherapy; however, 30%–40% of patients will have relapsed or refractory (R/R) disease. Of these patients, those with refractory or early relapsed LBCL may receive chimeric antigen receptor (CAR) T‐cell therapy as their second‐line treatment if they are eligible, and those with late relapse may instead receive high‐dose chemotherapy with autologous stem cell transplantation, recently licensed second‐line bispecific antibody with chemotherapy, other targeted agents, or palliative management only. This narrative review aims to summarize the data for CAR T‐cell therapy as a curative‐intent treatment for R/R LBCL based on available evidence. This evidence includes long‑term follow‑up data from the Phase 3 ZUMA‑7 and TRANSFORM trials, as well as other CAR T‐cell therapy studies, which suggest the potential for CAR T‑cell therapy to achieve durable, possibly curative outcomes in R/R LBCL. Both studies show clear plateaus in Kaplan–Meier survival curves around 2 years, with sustained remissions extending to 5 years. These data offer a compelling perspective on the curative potential of CAR T‐cell therapy while underscoring the need for continued follow‑up and broader analyses.

Autor:innen und Institutionen

  • Wilmot Cancer Institute University of Rochester Medical Center Rochester New York United States of America.
  • Northern Centre for Cancer Care Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle Upon Tyne United Kingdom.
  • Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle University Newcastle Upon Tyne United Kingdom.

ORCID-Profile: Danielle S Wallace, Wendy Osborne

Zitieren

APA

Wallace, D. S., Gupta, Y., Casulo, C., & Osborne, W. (2026). Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma. HemaSphere, 10(11). https://doi.org/10.1002/hem3.70489

Vancouver

Wallace DS, Gupta Y, Casulo C, Osborne W. Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma. HemaSphere. 2026;10(11). doi:10.1002/hem3.70489

BibTeX
@article{Wallace2026,
  author = {Wallace, Danielle S and Gupta, Yashashree and Casulo, Carla and Osborne, Wendy},
  title = {Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1002/hem3.70489}
}
Kostenlos starten →